Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
177Lu-fresolimumab
- Development stage
- Preclinical
- Lead developer
- University of California, San Francisco
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
177Lu-fresolimumab is a preclinical-stage therapeutic radiopharmaceutical consisting of the pan-TGFβ-neutralizing monoclonal antibody fresolimumab conjugated to the beta-emitting radionuclide lutetium-177 (177Lu) via a DOTA chelator. Developed by the University of California, San Francisco (UCSF), it targets transforming growth factor beta (TGFβ), which is highly active and dysregulated in the tumor microenvironment of various cancers. By delivering targeted radiation to sites of active TGFβ, 177Lu-fresolimumab aims to treat solid tumors, particularly those with high TGFβ activity or where external beam radiation therapy can prime and enhance its uptake.
- Other names
- 177Lu-DOTA-fresolimumab177Lu-freso[177Lu]Lu-fresolimumablutetium (177Lu) fresolimumab
02
Targets
TGFB1 (Transforming growth factor Beta-1 proprotein)TGFB2 (Transforming growth factor beta 2)TGFB3 (Transforming growth factor beta 3)
Beyond the preview
Go deeper on 177Lu-fresolimumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 177Lu-fresolimumab.